Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Columbia University Medical Center
mi
from
New York, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Cleveland Clinic
mi
from
Cleveland, OH
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
The West Clinic, PC
mi
from
Memphis, TN
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Northwest Medical Specialists
mi
from
Tacoma, WA
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Northwest Medical Specialists
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Stanford Cancer Center
mi
from
Stanford, CA
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Washington University School of Medicine
mi
from
St. Louis, MO
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Centre hospitalier de l'Universite de Montreal (CHUM)
mi
from
Montreal,
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Centre hospitalier de l'Universite de Montreal (CHUM)
mi
from
Montreal,
Click here to add this to my saved trials
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Status: Enrolling
Updated:  1/8/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Status: Enrolling
Updated: 1/8/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Status: Enrolling
Updated:  1/8/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Status: Enrolling
Updated: 1/8/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated:  1/11/2016
Brachytherapy Site: Urology Centers of Alabama
mi
from
Birmingham, AL
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated: 1/11/2016
Brachytherapy Site: Urology Centers of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated:  1/11/2016
Brachytherapy Site: Specialists in Urology
mi
from
Naples, FL
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated: 1/11/2016
Brachytherapy Site: Specialists in Urology
mi
from
Naples, FL
Click here to add this to my saved trials
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated:  1/11/2016
Brachytherapy Site: Grand Strand Urology
mi
from
Myrtle Beach, SC
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated: 1/11/2016
Brachytherapy Site: Grand Strand Urology
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated:  1/11/2016
HIFU Site: Southeast Urology Network
mi
from
Memphis, TN
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated: 1/11/2016
HIFU Site: Southeast Urology Network
mi
from
Memphis, TN
Click here to add this to my saved trials
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated:  1/11/2016
HIFU Site: Urology of San Antonio
mi
from
San Antonio, TX
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated: 1/11/2016
HIFU Site: Urology of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated:  1/11/2016
HIFU Site: Urology Associates
mi
from
Nashville, TN
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU
Status: Enrolling
Updated: 1/11/2016
HIFU Site: Urology Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
David Geffen School of Medicine at University of California Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Tower Urology
mi
from
Los Angeles, CA
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Tower Urology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Walter Reed National Military Medical Center (Military Personnel Only)
mi
from
Washington,
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Walter Reed National Military Medical Center (Military Personnel Only)
mi
from
Washington,
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Specialists in Urology
mi
from
Naples, FL
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Specialists in Urology
mi
from
Naples, FL
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Indiana University
mi
from
Indianapolis, IN
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Metropolitan Urology, PSC
mi
from
Jeffersonville, IN
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Metropolitan Urology, PSC
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Tulane University
mi
from
New Orleans, LA
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
New York University School of Medicine
mi
from
New York, NY
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
University of Cincinnati
mi
from
Cincinnati, OH
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
University Hospitals of Cleveland / Case Medical Center
mi
from
Cleveland, OH
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
University Hospitals of Cleveland / Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Urologic Consultants of SE PA, LLP
mi
from
Bala Cynwyd, PA
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Urologic Consultants of SE PA, LLP
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated:  1/11/2016
London Health Sciences Centre
mi
from
London,
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
Status: Enrolling
Updated: 1/11/2016
London Health Sciences Centre
mi
from
London,
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
La Verne, CA
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
La Verne, CA
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Honolulu, HI
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Urbana, IL
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Urbana, IL
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Metairie, LA
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Burlington, MA
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Kansas City, MO
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated:  1/11/2016
Clinical Research Facility
mi
from
Omaha, NE
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Status: Enrolling
Updated: 1/11/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials